Discovery Life Sciences, Inc.
1236 Los Osos Valley Road
About Discovery Life Sciences, Inc.
Discovery Life Sciences is an innovative clinical research products and services company serving the life sciences industry by delivering clinical research specimens, patient samples and human bio-fluids combined with complex annotated data sets and a wide range of clinical research services from proprietary platforms in support of novel biomarker assays, detection technologies and instrument platforms in analytical and clinical development. Our Magellan, e-commerce based, bio-repository of >200,000 specimens can ship globally within 24-48 hours.
Areas of focus include but are not limited to; infectious diseases, oncology, fetal-maternal health, cardiac diseases, autoimmune and endocrine diseases, metabolic syndrome, flu and related respiratory illness, bacterial, viral and parasitic diseases, normal control patient populations. Our Discovery Partners™ Program consists of >100 contracted clinical sites in hospital networks, academic medical centers, blood banks, clinical laboratories and community based medical practices worldwide.
Our fully integrated clinical research services include study assessment, complex protocol development, IRB submissions and approval, clinical site and principle investigator identification and selection, clinical site contracting, site monitoring, management & close out, document management, study specific collection kits, comprehensive human bio-sample program management, inventory management, cold storage, global distribution logistics.
We provide biostorage services at no charge for clients that we do clinical studies for.
13 articles with Discovery Life Sciences, Inc.
Discovery Life Sciences™, the biospecimen and biomarker specialists™, announced that it has acquired Targos Molecular Pathology GmbH, Germany, one of the largest molecular pathology laboratories in Europe, to significantly expand its global tissue biomarker services.
Discovery Life Sciences Launches TruSight Oncology 500 (TSO500) Solid Tumor FFPE and cfDNA Services to Advance Liquid Biopsy Development and Immunotherapy Clinical Research
Discovery Life Sciences™, a global leader in biospecimen solutions, genomic, cell, and immunohistochemistry services, announces the addition of Illumina's TruSight Oncology 500 technology to HudsonAlpha Discovery, Discovery's highly recognized and regarded sequencing and bioinformatics laboratory.
Discovery Life Sciences Expands their PacBio Center of Excellence to Become One of the Largest Commercial Long Read Sequencing Services Laboratories in the World
Solidifying Discovery's Role as a Leader in Long Read Sequencing and Creating Large-Scale Long Read and Short Read Sequencing Services
Discovery Life Sciences Expands Immunomonitoring Services To Accelerate Development Of New Cell Therapies
Discovery Life Sciences™(Discovery), a global leader in biospecimen solutions, genomic, cell, and immunohistochemical (IHC) services, today announced the significant expansion of its cell biology and immunology services laboratory, specifically to accelerate discovery, preclinical, and clinical development of new cell therapies and immunotherapeutics.
Discovery Life Sciences Continues Expansion Through The Acquisition Of Leading Immunohistochemistry Service Laboratories
Discovery's Services Uniquely Support Preclinical, Translational, and Clinical Research through Biospecimen Procurement, Multiomic Annotation, and Bioinformatic Analysis
Significant Investment to Accelerate Cancer Research Creates First Commercial Single Source for Combined FFPE Acquisition, FFPE RNA Isolation and Long-Read Sequencing
Highest Quality, Characterization, Exceptional Pricing, and Overnight Arrival Provide Best Industry Value
Discovery Life Sciences Adds The HudsonAlpha Genomic Services Laboratory To Expand Scientific Capabilities
New Leading Global Provider of Bioscience, Biospecimen, Sequencing, and Bioinformatic Services Will Speed Time from Discovery to Breakthrough
Cements Position as Global Biospecimen Leader
MERGER CREATES NEW GLOBAL LEADER IN BIOSPECIMEN SOLUTIONS: FOUR COMPANIES UNITE TO FORM DISCOVERY LIFE SCIENCES
Conversant Bio, Folio Bio, Discovery Life Sciences and Phylogeny announced today that they have merged under the name Discovery Life Sciences™ (Discovery) to create a global market leader in biospecimen analysis and procurement for the pharmaceutical, biotechnology and diagnostics industries.
Discovery Life Sciences, a leading research biobank located in Los Osos, California, recently got much, much bigger via a four-company merger. Ann Dover, Discovery’s founder, president and CEO, took time to speak with BioSpace about the merger and the new identity of the company.
Discovery Life Sciences Announces Major Expansion Of Its Clinical Research Network To Support Novel Cancer, Hepatitis, HIV, And Women's Health Test Development With Complex Human Biospecimens.
Discovery Life Sciences Introduces Magellan -- An Innovative WEB Based Biobank Delivering Human Biospecimens To Advance Novel Biomarker Tests In Clinical Development